ESLAW
Estrella Immunopharma, Inc.
Nasdaq Biological Products, (No Diagnostic Substances)
Emerging growth company

Key Financials

Operating Income
$-13062674
↓ 195.1%
Net Income
$-13063512
↓ 195.1%
EPS (Diluted)
$-0.35
↓ 191.7%
Total Assets
$3.2M
↑ 1.2%
Total Liabilities
$13.5M
↑ 351.9%
Cash & Equivalents
$1.4M
↑ 51.0%
Shareholders' Equity
$-10366058.00
↓ 7312.1%
Operating Cash Flow
$-1785679.00
↑ 42.6%

Recent SEC Filings

Form Type Filed Date Link
8-K 6/30/2026 View on SEC
DEF 14A 5/27/2026 View on SEC
10-Q 5/18/2026 View on SEC
NT 10-Q 5/18/2026 View on SEC
SCHEDULE 13G 5/15/2026 View on SEC
10-K/A 4/30/2026 View on SEC
4 4/29/2026 View on SEC
10-K 3/18/2026 View on SEC
424B3 2/13/2026 View on SEC
EFFECT 1/23/2026 View on SEC

Company Information

Field Value
Ticker ESLAW
Company Name Estrella Immunopharma, Inc.
CIK 1844417
Sector Biological Products, (No Diagnostic Substances)
Industry
Emerging growth company
Exchange Nasdaq
SIC Code 2836
SIC Description Biological Products, (No Diagnostic Substances)
Entity Type operating
Fiscal Year End 1231
Phone (510) 318-9098